WO1998046781A3 - Novel transgene expression system for increased persistence - Google Patents
Novel transgene expression system for increased persistence Download PDFInfo
- Publication number
- WO1998046781A3 WO1998046781A3 PCT/US1998/007841 US9807841W WO9846781A3 WO 1998046781 A3 WO1998046781 A3 WO 1998046781A3 US 9807841 W US9807841 W US 9807841W WO 9846781 A3 WO9846781 A3 WO 9846781A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression system
- transgene expression
- transgene
- directed
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98918409A EP0975786A2 (en) | 1997-04-14 | 1998-04-14 | Novel transgene expression system for increased persistence |
CA002287076A CA2287076A1 (en) | 1997-04-14 | 1998-04-14 | Novel transgene expression system for increased persistence |
JP54434398A JP2001521390A (en) | 1997-04-14 | 1998-04-14 | Novel transgene expression system for enhanced persistence |
AU71336/98A AU7133698A (en) | 1997-04-14 | 1998-04-14 | Novel transgene expression system for increased persistence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/839,552 | 1997-04-14 | ||
US08/839,552 US5981275A (en) | 1997-04-14 | 1997-04-14 | Transgene expression system for increased persistence |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998046781A2 WO1998046781A2 (en) | 1998-10-22 |
WO1998046781A3 true WO1998046781A3 (en) | 1999-01-21 |
Family
ID=25280040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/007841 WO1998046781A2 (en) | 1997-04-14 | 1998-04-14 | Novel transgene expression system for increased persistence |
Country Status (6)
Country | Link |
---|---|
US (1) | US5981275A (en) |
EP (1) | EP0975786A2 (en) |
JP (1) | JP2001521390A (en) |
AU (1) | AU7133698A (en) |
CA (1) | CA2287076A1 (en) |
WO (1) | WO1998046781A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2705686B1 (en) | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
DE69633565T3 (en) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY |
IL135578A0 (en) * | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
AU750803B2 (en) | 1997-10-29 | 2002-07-25 | University Of Pittsburgh | Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies |
WO1999036557A1 (en) * | 1998-01-16 | 1999-07-22 | Genzyme Corporation | Novel promoter elements for persistent gene expression |
EP0974668B1 (en) * | 1998-07-07 | 2002-10-02 | Transgene S.A. | Use of adenoviral E4 reading frames to improve expression of a gene of interest |
WO2000012740A2 (en) | 1998-08-28 | 2000-03-09 | Duke University | ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES |
US6440944B2 (en) * | 1998-10-16 | 2002-08-27 | Genvec, Inc. | Methods of administering adenoviral vectors |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
DE19900284B4 (en) * | 1999-01-07 | 2008-02-07 | Ingo Prof. Dr. Schmidt-Wolf | Method for the efficient introduction of DNA into eukaryotic cells using an adenoviral vector |
ATE431421T1 (en) * | 1999-01-28 | 2009-05-15 | Onyx Pharma Inc | ADENOVIRAL SHUTTLE VECTORS DELETED IN THE E1B REGION |
US6764674B1 (en) | 1999-01-28 | 2004-07-20 | Onyx Pharmaceuticals Inc. | Adenovirus E1B shuttle vectors |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7468181B2 (en) * | 2002-04-25 | 2008-12-23 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
AU2001259174A1 (en) * | 2000-04-28 | 2001-11-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies |
US6649597B1 (en) | 2000-06-22 | 2003-11-18 | The University Of Iowa Research Foundation | Targeting vector to the urokinase plasminogen activator receptor |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
JP2004516016A (en) * | 2000-09-18 | 2004-06-03 | ジェンザイム・コーポレイション | Expression vector containing hybrid ubiquitin promoter |
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
JP2005529959A (en) * | 2002-06-14 | 2005-10-06 | マイラス コーポレイション | Novel method for delivering polynucleotides to cells |
EP2287341B1 (en) | 2003-12-01 | 2013-02-13 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028938A1 (en) * | 1993-06-07 | 1994-12-22 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy sponsorship |
WO1996013596A1 (en) * | 1994-10-28 | 1996-05-09 | Rhone-Poulenc Rorer S.A. | Viable contaminant particle free adenoviruses, their preparation and use |
WO1996018372A2 (en) * | 1994-12-09 | 1996-06-20 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
WO1996030534A1 (en) * | 1995-03-24 | 1996-10-03 | Genzyme Corporation | Adenovirus vectors for gene therapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5635380A (en) * | 1994-01-18 | 1997-06-03 | Vanderbilt University | Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids |
US5719131A (en) * | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
CA2625279A1 (en) * | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
-
1997
- 1997-04-14 US US08/839,552 patent/US5981275A/en not_active Expired - Fee Related
-
1998
- 1998-04-14 EP EP98918409A patent/EP0975786A2/en not_active Withdrawn
- 1998-04-14 AU AU71336/98A patent/AU7133698A/en not_active Abandoned
- 1998-04-14 CA CA002287076A patent/CA2287076A1/en not_active Abandoned
- 1998-04-14 WO PCT/US1998/007841 patent/WO1998046781A2/en not_active Application Discontinuation
- 1998-04-14 JP JP54434398A patent/JP2001521390A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028938A1 (en) * | 1993-06-07 | 1994-12-22 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy sponsorship |
WO1996013596A1 (en) * | 1994-10-28 | 1996-05-09 | Rhone-Poulenc Rorer S.A. | Viable contaminant particle free adenoviruses, their preparation and use |
WO1996018372A2 (en) * | 1994-12-09 | 1996-06-20 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
WO1996030534A1 (en) * | 1995-03-24 | 1996-10-03 | Genzyme Corporation | Adenovirus vectors for gene therapy |
Non-Patent Citations (1)
Title |
---|
BRIDGE, E. ET AL.: "Adenovirus early region 4 and viral DNA synthesis", VIROLOGY, vol. 193, 1993, pages 794 - 801, XP002051623 * |
Also Published As
Publication number | Publication date |
---|---|
AU7133698A (en) | 1998-11-11 |
CA2287076A1 (en) | 1998-10-22 |
JP2001521390A (en) | 2001-11-06 |
WO1998046781A2 (en) | 1998-10-22 |
EP0975786A2 (en) | 2000-02-02 |
US5981275A (en) | 1999-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998046781A3 (en) | Novel transgene expression system for increased persistence | |
WO2003023000A3 (en) | Linear dna fragments for gene expression | |
CA2205874A1 (en) | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy | |
CA2187626A1 (en) | Aav-mediated delivery of dna to cells of the nervous system | |
WO2000018906A3 (en) | Shuffling of codon altered genes | |
JPS6485084A (en) | Constellation of protein c | |
MX9709549A (en) | Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses. | |
PL331005A1 (en) | Regulating dna of hamster's ef-1alpha transcription | |
WO1998045456A8 (en) | 2-deoxyglucose-6-phosphate (2-dog-6-p) phosphatase dna sequences as selection markers in plants | |
WO1996005309A3 (en) | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof | |
AP1678A (en) | Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems. | |
CA2311643A1 (en) | Compositions and methods for inducing gene expression | |
WO2000073478A3 (en) | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration | |
CA2274314A1 (en) | Insulin-like growth factor i (igf-i) expression system and methods of use | |
CA2309755A1 (en) | Hormone-dependent forms of the adeno-associated virus, rep proteins, dna sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity | |
IL148785A0 (en) | Vectors and methods for recombinant protein expression | |
WO1997035005A3 (en) | Cftr gene regulator | |
WO2003093485A3 (en) | Optimization of transgene expression in mammalian cells | |
WO1999047678A3 (en) | Interferon alpha plasmids and delivery systems, and methods of making and using the same | |
CA2264962A1 (en) | Transcription factor controlling phenylpropanoid biosynthesis pathway | |
WO1998040498A3 (en) | Immunoadhesins and methods of production and use thereof | |
AU5587198A (en) | Methods for preparing nucleotide integrases | |
WO2000006759A3 (en) | Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same | |
WO2004033653A3 (en) | Gene regulation with aptamer and modulator complexes for gene therapy | |
HUP0101355A2 (en) | Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 71336/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09416672 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2287076 Country of ref document: CA Ref country code: CA Ref document number: 2287076 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 544343 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998918409 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998918409 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998918409 Country of ref document: EP |